<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://mindmedicinelaw.com/briefing/non-hallucinogenic-ketamine-for-trauma-israeli-clinical-trials-and-global-implic-20261122-61035</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:06.315414+00:00</news:publication_date><news:title>Non-Hallucinogenic Ketamine for Trauma: Israeli Clinical Trials and Global Implications</news:title><news:keywords>ketamine, non-hallucinogenic, israel, trauma treatment, clinical trials, psychedelic research, regulatory policy, ptsd, neuropharmacology</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mechanism-aligned-ketamine-therapy-2026-update-for-trd-20261120-60866</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:51.419375+00:00</news:publication_date><news:title>Mechanism-Aligned Ketamine Therapy: 2026 Update for TRD</news:title><news:keywords>ketamine therapy, treatment-resistant depression, mechanism-aligned care, neuroplasticity, psychedelic therapy, clinical protocols, safety considerations, patient selection, contextual integration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/lsd-clinical-trials-global-phase-3-efforts-and-evidence-gaps-20261120-60820</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:05:59.479457+00:00</news:publication_date><news:title>LSD Clinical Trials: Global Phase 3 Efforts and Evidence Gaps</news:title><news:keywords>lsd clinical trials, phase 3 lsd studies, microdosing efficacy, anxiety and depression, pain disorders, psychedelic research, regulatory challenges, trial design, evidence gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/hhs-unveils-major-federal-funding-for-psychedelic-research-ibogaine-emphasis-20261120-60821</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:05:49.798432+00:00</news:publication_date><news:title>HHS Unveils Major Federal Funding for Psychedelic Research, Ibogaine Emphasis</news:title><news:keywords>hhs psychedelic funding, ibogaine research, nimh grants, arpa-h, psychedelic clinical trials, federal policy, mental health innovation, rapid-acting psychotropics, ptsd treatment research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/compass-pathways-faces-fda-approval-and-dea-scheduling-hurdles-in-us-20261120-60779</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:03:53.181538+00:00</news:publication_date><news:title>Compass Pathways Faces FDA Approval and DEA Scheduling Hurdles in US</news:title><news:keywords>compass pathways, fda approval, dea scheduling, psilocybin therapy, controlled substances act, treatment-resistant depression, drug policy, clinical trials, rem, psychedelic medicine</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/us-house-panel-advances-psychedelic-mental-health-care-for-veterans-20261120-60686</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:02.126291+00:00</news:publication_date><news:title>US House Panel Advances Psychedelic Mental Health Care for Veterans</news:title><news:keywords>psychedelic policy, veterans mental health, us congress, bipartisan support, ptsd treatment, va clinical trials, federal research funding, mdma therapy, regulatory barriers, psychedelic access</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/translational-limits-of-animal-models-in-psychedelic-research-20261119-61031</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:14.406572+00:00</news:publication_date><news:title>Translational Limits of Animal Models in Psychedelic Research</news:title><news:keywords>animal models, psychedelic research, translational challenges, preclinical studies, human clinical trials, regulatory policy, safety assessment, serotonin receptors, drug development, neuroscience</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/nirs-water-analysis-implications-for-psychedelic-drug-quality-control-20261119-60841</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:05.862707+00:00</news:publication_date><news:title>NIRS Water Analysis: Implications for Psychedelic Drug Quality Control</news:title><news:keywords>near-infrared spectroscopy, water analysis, pharmaceutical quality control, psychedelic manufacturing, regulatory compliance, analytical quality by design, critical quality attributes, nutraceutical authenticity, ICH Q14, process analytical technology</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/glymphatic-system-as-a-novel-target-in-treatment-resistant-depression-20261119-60857</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:55.481194+00:00</news:publication_date><news:title>Glymphatic System as a Novel Target in Treatment-Resistant Depression</news:title><news:keywords>glymphatic system, treatment-resistant depression, psychedelics, ketamine, sleep architecture, astrocytes, major depressive disorder, neuroimaging, biomarkers, clinical research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/second-generation-nmdar-pams-implications-for-neuropsychiatric-drug-development-20261119-60867</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:46.887615+00:00</news:publication_date><news:title>Second-Generation NMDAR PAMs: Implications for Neuropsychiatric Drug Development</news:title><news:keywords>nmdar positive allosteric modulators, thieno[2,3-d]pyrimidin-4-one derivatives, neuropsychiatric drug development, glun2d subunit, rapid-acting antidepressants, preclinical research, oral bioavailability, cns therapeutics, mechanistic insights, translational challenges</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/simulated-weightlessness-depersonalisation-and-the-self-implications-for-psyched-20261119-60858</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:36.852581+00:00</news:publication_date><news:title>Simulated Weightlessness, Depersonalisation, and the Self: Implications for Psychedelic Neuroscience</news:title><news:keywords>simulated weightlessness, depersonalisation, vestibular system, ego dissolution, psychedelic research, gravity neuroscience, multisensory integration, altered states of consciousness, cambridge depersonalisation scale, space medicine</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/historeceptomics-sheds-light-on-ketamine-s-brain-targets-20261119-60860</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:17.197017+00:00</news:publication_date><news:title>Historeceptomics Sheds Light on Ketamine's Brain Targets</news:title><news:keywords>ketamine, historeceptomics, nmda receptor, antidepressant mechanism, brain region mapping, clinical implications, psychedelic research, drug development, adverse effects, policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/translational-gaps-in-animal-models-for-psychedelic-research-20261119-60822</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:20.560589+00:00</news:publication_date><news:title>Translational Gaps in Animal Models for Psychedelic Research</news:title><news:keywords>animal models, psychedelic research, translational gap, set and setting, preclinical studies, behavioral assays, individual differences, social context, regulatory science, experimental design</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-assisted-treatment-for-suds-evidence-and-gaps-2026-review-20261119-60824</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:11.736436+00:00</news:publication_date><news:title>Psychedelic-Assisted Treatment for SUDs: Evidence and Gaps (2026 Review)</news:title><news:keywords>psychedelic-assisted therapy, substance use disorders, clinical trials, policy, public health, psilocybin, regulatory oversight, treatment efficacy, integration with psychotherapy, risk assessment</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/shared-astrocytic-signalling-pathways-in-diverse-psychoactives-insights-from-mul-20261119-60856</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:02.036416+00:00</news:publication_date><news:title>Shared Astrocytic Signalling Pathways in Diverse Psychoactives: Insights from Multi-Omics Analysis</news:title><news:keywords>astrocytes, psychoactive drugs, multi-omics, psilocin, substance use disorder, cytoskeletal signalling, rho-gtpase, neurobiology, translational research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/biosynthetic-pathway-discovery-for-carbolines-in-ayahuasca-plants-20261119-60859</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:30.477960+00:00</news:publication_date><news:title>Biosynthetic Pathway Discovery for β-Carbolines in Ayahuasca Plants</news:title><news:keywords>β-carboline biosynthesis, ayahuasca research, DMT production, psychedelic clinical trials, plant biotechnology, standardized psychedelics, conservation, regulatory implications, intellectual property, indigenous rights</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/distinct-brain-reconfiguration-after-psilocybin-vs-escitalopram-in-depression-ne-20261119-60823</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:19.178985+00:00</news:publication_date><news:title>Distinct Brain Reconfiguration After Psilocybin vs. Escitalopram in Depression: New fMRI Modelling Insights</news:title><news:keywords>psilocybin, escitalopram, major depressive disorder, fMRI, brain network reconfiguration, vortex-space modelling, biomarkers, clinical trials, psychedelic mechanisms</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-as-a-cgrp-inhibitor-in-hnscc-preclinical-insights-20261119-60861</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:10.320463+00:00</news:publication_date><news:title>Psilocybin as a CGRP Inhibitor in HNSCC: Preclinical Insights</news:title><news:keywords>psilocybin, cgrp inhibition, head and neck squamous cell carcinoma, neuroimmune oncology, tumor microenvironment, preclinical research, immunotherapy, serotonin, psychedelic compounds, translational research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/addiction-professionals-assess-psychedelics-for-aud-prevention-in-us-20261119-60573</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:42.362366+00:00</news:publication_date><news:title>Addiction Professionals Assess Psychedelics for AUD Prevention in US</news:title><news:keywords>psychedelics, alcohol use disorder, prevention, addiction professionals, policy barriers, clinical trials, equity in access, public health, workforce training</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/meta-analysis-of-psilocybin-and-lsd-for-anxiety-rct-evidence-review-20261119-60610</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:30.541779+00:00</news:publication_date><news:title>Meta-Analysis of Psilocybin and LSD for Anxiety: RCT Evidence Review</news:title><news:keywords>psilocybin, LSD, anxiety disorders, systematic review, meta-analysis, dose-response, randomized controlled trials, psychedelic therapy, safety profile</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mescaline-s-empathy-effects-5-ht2a-mechanism-in-human-study-20261119-60572</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:26.568417+00:00</news:publication_date><news:title>Mescaline’s Empathy Effects: 5-HT2A Mechanism in Human Study</news:title><news:keywords>mescaline, empathy, 5-HT2A receptor, oxytocin, psychedelic clinical trials, serotonergic psychedelics, psychiatric research, empathogenic effects, placebo-controlled study, policy implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/adverse-outcomes-after-psychedelic-therapy-u-s-clinical-and-policy-implications-20261119-60688</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:14.026509+00:00</news:publication_date><news:title>Adverse Outcomes After Psychedelic Therapy: U.S. Clinical and Policy Implications</news:title><news:keywords>psychedelic therapy, adverse outcomes, post-treatment support, informed consent, clinical trials, FDA guidance, integration protocols, risk communication, patient safety</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/stagic-advances-brain-circuit-modeling-for-psychedelic-research-20261118-60830</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:23.740266+00:00</news:publication_date><news:title>StaGIC Advances Brain Circuit Modeling for Psychedelic Research</news:title><news:keywords>stagic, brain circuit modeling, psychedelic research, structural connectivity, functional connectivity, neuroimaging biomarkers, clinical trials, computational psychiatry, diffusion mri, circuit heterogeneity</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/compassion-outcomes-in-psychedelic-therapy-evidence-and-gaps-20261118-60843</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:27.036494+00:00</news:publication_date><news:title>Compassion Outcomes in Psychedelic Therapy: Evidence and Gaps</news:title><news:keywords>self-compassion, compassion for others, psychedelic therapy, mdma, psilocybin, clinical trials, mechanistic studies, measurement gaps, therapeutic outcomes, regulatory implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/non-hallucinogenic-psychedelic-analogs-for-depression-mechanisms-and-implication-20261118-60833</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:41.429630+00:00</news:publication_date><news:title>Non-Hallucinogenic Psychedelic Analogs for Depression: Mechanisms and Implications</news:title><news:keywords>non-hallucinogenic psychedelics, antidepressant analogs, neuroplasticity, 5-HT2A receptor, drug design, depression treatment, regulatory barriers, clinical trials, psychoplastogens</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/monoamine-targeting-drugs-for-ptsd-efficacy-mechanisms-and-implications-20261118-60592</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:17.428400+00:00</news:publication_date><news:title>Monoamine-Targeting Drugs for PTSD: Efficacy, Mechanisms, and Implications</news:title><news:keywords>ptsd, monoamine targeting drugs, ssri, sertraline, paroxetine, off-label treatments, psychedelic therapeutics, mechanistic rationale, clinical trials, treatment gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/prescribed-safer-supply-in-british-columbia-early-outcomes-and-policy-implicatio-20261118-60611</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:04.935422+00:00</news:publication_date><news:title>Prescribed Safer Supply in British Columbia: Early Outcomes and Policy Implications</news:title><news:keywords>prescribed safer supply, british columbia, harm reduction, depression, unregulated substance use, public health policy, cohort study, drug policy, service integration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/eeg-fmri-fusion-methods-implications-for-psychedelic-neuroscience-20261118-60622</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:53.046334+00:00</news:publication_date><news:title>EEG-fMRI Fusion Methods: Implications for Psychedelic Neuroscience</news:title><news:keywords>eeg-fmri fusion, psychedelic neuroscience, multimodal neuroimaging, latent neural inference, clinical trial endpoints, biomarker development, interpretability challenges, validation standards, nonlinear modeling</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/lsd-and-first-episode-psychosis-neural-overlap-revealed-in-connectome-study-20261118-60577</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:07.015923+00:00</news:publication_date><news:title>LSD and First Episode Psychosis: Neural Overlap Revealed in Connectome Study</news:title><news:keywords>lsd, first episode psychosis, connectome, resting-state functional connectivity, dorsal attention network, sensorimotor network, psychotomimetic, psychedelic therapy, risk assessment, clinical trial design</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/hospital-management-of-ketamine-use-clinical-challenges-and-policy-implications-20261118-60626</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:56.123731+00:00</news:publication_date><news:title>Hospital Management of Ketamine Use: Clinical Challenges and Policy Implications</news:title><news:keywords>ketamine use disorder, hospital management, acute intoxication, withdrawal treatment, chronic complications, harm reduction, clinical protocols, policy implications, substance use screening</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/dissociation-in-esketamine-therapy-clinical-impact-and-practice-in-israel-20261118-60623</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:37.410458+00:00</news:publication_date><news:title>Dissociation in Esketamine Therapy: Clinical Impact and Practice in Israel</news:title><news:keywords>esketamine therapy, dissociation, treatment-resistant depression, trauma comorbidity, integration support, psychedelic-assisted therapy, clinical outcomes, israel mental health, antidepressant efficacy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-augmented-psychotherapy-and-neurocognition-in-unipolar-depression-2026--20261117-60877</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:33.910417+00:00</news:publication_date><news:title>Ketamine-Augmented Psychotherapy and Neurocognition in Unipolar Depression: 2026 Scoping Review</news:title><news:keywords>ketamine-augmented psychotherapy, unipolar depression, neurocognitive outcomes, scoping review, treatment-resistant depression, clinical trial design, cognitive assessment, psychedelic research, evidence mapping</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/trkb-as-a-unifying-target-rethinking-serotoninergic-antidepressants-and-psychede-20261116-60579</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:18.879298+00:00</news:publication_date><news:title>TrkB as a Unifying Target: Rethinking Serotoninergic Antidepressants and Psychedelics</news:title><news:keywords>trkB, serotonin transporter, ssri mechanism, psychedelic antidepressants, bdnf signaling, clinical trial design, biomarkers, regulatory policy, neuroplasticity</news:keywords></news:news></url></urlset>